Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05321563 · ClinicalTrials.gov registry record · NA
Evaluating the Effectiveness of a Drug Education and Diversion Program for Middle and High School Students
A NA study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- NA
- Development phase
- 132
- Enrollment target
NCT05321563: Clinical Trial NA study, sponsored by Massachusetts General Hospital.
NCT05321563 is a NA study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 132 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05321563, a NA study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- NA
- Development phase
- 132 participants
- Enrollment target
Study Summary
The primary goal of this study is to evaluate the effectiveness of the iDECIDE curriculum as an alternative to punitive responses for school-based substance use infractions.
Primary Outcome
Knowledge of drug effects will be measured by number of items correct on a survey examining a student's understanding of adolescent brain development, neurobiology of addiction, and the impact of alcohol, cannabis, nicotine and other substance use on the brain and body.
Interventions
- BEHAVIORAL iDECIDE (Drug Education Curriculum: Intervention, Diversion, and Empowerment)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2022-02-04 |
| Est. Completion | 2023-09-14 |
| Phase | NA |
Why NCT05321563 stopped before completion
NCT05321563 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 1 intervention - of which iDECIDE (Drug Education Curriculum: Intervention, Diversion, and Empowerment) is the first listed.
NCT05321563 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05321563 about?
NCT05321563 is a clinical study titled "Evaluating the Effectiveness of a Drug Education and Diversion Program for Middle and High School Students". The primary goal of this study is to evaluate the effectiveness of the iDECIDE curriculum as an alternative to punitive responses for school-based substance use infractions.
What is the current status of trial NCT05321563?
This trial is currently terminated. It is a NA study. The enrollment target is 132 participants. The study started on 2022-02-04. Estimated completion is 2023-09-14.
What interventions are being tested in trial NCT05321563?
The interventions under investigation include: iDECIDE (Drug Education Curriculum: Intervention, Diversion, and Empowerment) (BEHAVIORAL).
Who is sponsoring clinical trial NCT05321563?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05321563's enrollment target sits among peer trials
132 729th of 2000 higher than 1,269 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI